Drugs / POSIZOLID
POSIZOLID
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01116258 | Apr → Oct 2010 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01037725 | Dec 2009 → Apr 2010 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT01516203 | Dec 2012 → Dec 2013 | tuberculosis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | Met primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | POSIZOLID | ChEMBL registry synonym — accepted as the source's own label CHEMBL131854 ↗ |
| Known as | AZD-2563 | ChEMBL registry synonym — accepted as the source's own label CHEMBL131854 ↗ |
| Known as | AZD5847 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01116258 ↗ |
| Modality | Small molecule | — CHEMBL131854 ↗ |
| Route | Oral | “Oral doses of AZD5847 given to 1 cohort of 8 subjects” NCT01037725 ↗ |